| abstract |
A GLP-1 analog comprising a histidine residue in a position corresponding to position 31 of GLP-1 (7-37) (SEQ ID NO: 1), a glutamine residue in a position corresponding to position 34 of GLP 1 (7-37) (SEQ ID NO: 1) and a maximum of eight amino acid modifications compared to GLP-1 (7-37) (SEQ ID NO: 1); wherein the histidine residue is designated H31 and the glutamine residue is designated Q34; or a pharmaceutically acceptable salt, amide or ester thereof. |